New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2013
12:31 EDTRFMD, GS, CLMT, SONC, ZIOP, BRK.AOn The Fly: Midday Wrap
Stocks on Wall Street were higher right out of the gate and have not moved far from their opening levels near midday. Investors received a fair amount of domestic economic data, including better than expected reports on home prices and durable goods orders. The flip side, however, was some worse than expected consumer confidence and new home sales data. Despite the mixed data, the market seems intent on closing the quarter with its gains intact as the end of the month approaches... ECONOMIC EVENTS: In the U.S., overall orders for durable goods rose 5.7% in February, versus expectations for an increase of 3.9%. However, excluding transportation, orders slipped 0.5%, versus expectations for a 0.6% rise. The S&P/Case-Shiller 20-city home price index climbed 8.1% in the 12 months ending in January, after rising 6.8% a month earlier. New home sales dropped 4.6% to 411K in February, versus expectations for a decline to 414K. Consumer confidence fell 8.3 points to 59.7 in March, which was worse than the expected pull back to 69.0. The Richmond Fed manufacturing survey reading of 3 for March missed expectations for it to hold at 6... COMPANY NEWS: Goldman Sachs (GS) announced that it amended its warrant agreement with Berkshire Hathaway (BRK.A) to settle in terms of net shares in place of a cash settlement, quoting Berkshire's Chairman and CEO Warren Buffett as having said, "We intend to hold a significant investment in Goldman Sachs." Shares of Goldman, which rose early in the session, were down fractionally near noon... MAJOR MOVERS: Among the notable gainers were Sonic (SONC), which rose 8% following its earnings report, and RF Micro Devices (RFMD), which rallied nearly 6% after Oppenheimer upgraded the stock to an Outperform rating. Among the noteworthy losers was Ziopharm (ZIOP), which was downgraded by at least four analyst firms and plunged over 61% after terminating development of a cancer drug after a clinical study missed its goal. Also lower were shares of Calumet Specialty Products (CLMT), down 4% after an offering of 5.25M of its shares priced at $37.50... INDICES: Near midday, the Dow was up 74.84, or 0.52%, to 14,522.59; the Nasdaq was up 5.90, or 0.18%, to 3,241.20; and the S&P 500 was up 6.36, or 0.41%, to 1,558.05.
News For A;SONC;RFMD;ZIOP;CLMT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 24, 2015
16:20 EDTAAgilent to host analyst meeting
Subscribe for More Information
May 20, 2015
16:29 EDTAAgilent appoints Rodney Gonsalves as principal accounting officer
Subscribe for More Information
10:29 EDTZIOPOptions with decreasing implied volatility
Options with decreasing implied volatility: ZIOP KING ARIA CTRP WTW VHC XON KERX VIPS JCP
10:16 EDTZIOPHigh option volume stocks
Subscribe for More Information
May 19, 2015
11:59 EDTZIOPOptions with decreasing implied volatilit
Subscribe for More Information
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
10:37 EDTZIOPOptions with decreasing implied volatility
Options with decreasing implied volatility: NLNK ARWR CTRP ZIOP CLNE ARIA VHC AOL KING XON PEIX
May 15, 2015
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
May 14, 2015
05:52 EDTZIOPMizuho expects CAR T stocks to be volatile after ASCO abstract
Subscribe for More Information
May 13, 2015
10:02 EDTZIOPOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: A.O. Smith (AOS) initiated with a Hold at Gabelli... Bellicum Pharmaceuticals (BLCM) initiated with a Neutral at Guggenheim... Criteo (CRTO) initiated with a Hold at Evercore ISI... FleetCor (FLT) initiated with a Buy at Monness Crespi... Franco-Nevada (FNV) initiated with a Buy at Canaccord... Horizon Technology (HRZN) initiated with an Outperform at Oppenheimer... Merrimack (MACK) initiated with a Buy at Guggenheim... Mobileye (MBLY) initiated with a Sector Weight at Pacific Crest... Monroe Capital (MRCC) initiated with an Outperform at Oppenheimer... Royal Gold (RGLD) initiated with a Hold at Canaccord... Silver Wheaton (SLW) initiated with a Buy at Canaccord... U.S. Concrete (USCR) initiated with a Buy at Stifel... Ziopharm (ZIOP) initiated with a Neutral at Guggenheim.
08:08 EDTAAgilent volatility elevated into Q1 and sales outlook
Subscribe for More Information
06:26 EDTZIOPZiopharm initiated with a Neutral at Guggenheim
May 12, 2015
09:23 EDTZIOPIntrexon CEO says Ziopharm acqusition could be 'attractive' in future
Subscribe for More Information
05:55 EDTZIOPIntrexon price target lowered to $45 from $50 at Mizuho
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use